Protagonist Therapeutics, Inc.
PTGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,376 | $1,302 | $535 | $1,584 |
| - Cash | $97 | $187 | $126 | $124 |
| + Debt | $11 | $1 | $4 | $6 |
| Enterprise Value | $2,290 | $1,116 | $413 | $1,466 |
| Revenue | $434 | $60 | $27 | $27 |
| % Growth | 624.1% | 125.7% | -2.8% | – |
| Gross Profit | $434 | $60 | $27 | $27 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $254 | -$90 | -$128 | -$123 |
| % Margin | 58.4% | -150.6% | -481.6% | -449.9% |
| Net Income | $275 | -$79 | -$127 | -$126 |
| % Margin | 63.3% | -131.6% | -479.3% | -458.9% |
| EPS Diluted | 4.23 | -1.39 | -2.52 | -2.65 |
| % Growth | 404.3% | 44.8% | 4.9% | – |
| Operating Cash Flow | $184 | -$70 | -$108 | -$108 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $183 | -$71 | -$109 | -$109 |